Skip to main content

Day: May 6, 2020

Credit Agricole Sa: First Quarter 2020 Results – Crédit Agricole absorbs the Covid-19 impact and is mobilised for the economy

First Quarter 2020 Results                                                              Montrouge, May 6th 2020Crédit Agricole absorbs the Covid-19 impact and is mobilised for the economy          This press release comments on the results of Crédit Agricole S.A. and those of Crédit Agricole Group, which comprises the Crédit Agricole S.A. entities and the Crédit Agricole Regional Banks, which own 55.9% of Crédit Agricole S.A. Please see p.23 onwards of this press release for details of specific items, which are restated in the various indicators to calculate underlying income. A reconciliation between the stated income statement and the underlying income statement can be found from p.3 for Crédit Agricole Group and from p.7 for Crédit Agricole S.A.Crédit Agricole Group

Continue reading

NORBIT – Results for the first quarter of 2020

Trondheim, 6 May 2020: NORBIT, a global provider of tailored technology to carefully selected niches, today reported revenues for the first quarter of 2020 of NOK 151.6 million, down 4 per cent from the corresponding period in 2019. All the company’s business segments are somewhat affected by the covid-19 situation, whereas the Oceans segment is the most affected due to its´ global presence.“I am pleased to see that we have managed to maintain production and delivered orders as requested by customers, despite the demanding conditions. Although I am not pleased with our results for the quarter, I am very pleased with the way our organisation has handled this challenging situation,” says Per Jørgen Weisethaunet, CEO of NORBIT.Throughout 2019, NORBIT strengthened its organisation to position for growth, resulting in increased employee expenses....

Continue reading

NORBIT – Resultater for første kvartal 2020

Trondheim, 6. mai 2020: NORBIT, en global leverandør av skreddersydd teknologi til utvalgte nisjer, rapporterte i dag inntekter for første kvartal 2020 på 151,6 millioner kroner, tilsvarende en nedgang i omsetningen på 4 prosent fra samme periode i 2019. Alle selskapets forretningsområder er til en viss grad påvirket av covid-19 situasjonen, hvorav segmentet Oceans er mest påvirket på grunn av sin globale virksomhet.«Det er gledelig at vi har klart å opprettholde produksjonen og levert de ordrene kundene har bedt om, til tross for de krevende forholdene vi har operert under. Selv om jeg ikke er fornøyd med de finansielle resultatene dette kvartalet, så er jeg fornøyd med hvordan organisasjonen har håndtert denne utfordrende situasjonen,» sier Per Jørgen Weisethaunet, administrerende direktør i NORBIT.Gjennom 2019 styrket NORBIT sin organisasjon...

Continue reading

Schibsted ASA (SCHA/SCHB) – Interim Financial Statement Q1 2020

Today, Schibsted released its Q1 2020 results.Highlights of the quarterGroup revenues increased by 5 percent in Q1 2020Q1 revenues for Schibsted ex Adevinta decreased by 2 percent (4 percent currency adjusted)Q1 EBITDA for Schibsted ex Adevinta came in 32 percent lower than last year at NOK 285 millionNordic Marketplaces: Revenue growth slowdown particularly affected by COVID-19 from mid-March, leaving Norway revenues flat compared to last year, while revenues in Sweden increased driven by Motor. Underlying flat EBITDA margin in Norway, Sweden with lower margin driven by investments in sales and product and technology capabilities.News Media: Exceptional growth in traffic and digital subscription revenues in March, but substantial drop in advertising revenues due to COVID-19 from mid-March and gaming regulation in Sweden led to a significant...

Continue reading

Number of Shares and Voting Rights of Innate Pharma as at May 1, 2020

MARSEILLE, France, May 06, 2020 (GLOBE NEWSWIRE) — Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at May 1, 2020:(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes...

Continue reading

Celyad Appoints Seasoned Industry Executives to Board of Directors

MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Dr. Maria Koehler and Mr. Dominic Piscitelli have been appointed as independent members to its Board of Directors, effective as of March 24 and May 6, respectively.“We are delighted to announce the appointment of Dr. Maria Koehler and Mr. Dominic Piscitelli to our Board of Directors given the tremendous industry experience and wealth of knowledge both will offer Celyad as we continue to build an oncology-focused organization rich with expertise,” said Filippo Petti, Chief Executive Officer of Celyad. “We look forward to Maria’s strategic advice as we continue to advance key elements of our developmental...

Continue reading

Bone Therapeutics Provides First Quarter 2020 Business Update

Regulated informationStrong progress in regulatory and operational preparations to start mid/late-stage clinical studies of company’s advance pipeline assetsA total of €11 million financing secured, further strengthening cash positionGosselies, Belgium, 6 May 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today provides a business update for the first quarter ended 31 March 2020.“Bone Therapeutics has experienced an excellent start to 2020, despite the COVID-19 pandemic,” said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. “We have gathered regulatory approvals for the start of the next clinical trials of both JTA-004, Bone...

Continue reading

Bone Therapeutics fait le point sur ses activités du premier trimestre 2020

Information réglementée Accélération des préparatifs règlementaires et opérationnels en vue du lancement des études cliniques portant sur les produits les plus avancésRenforcement de la position de trésorerie via un financement garantis de 11 M€ Gosselies, Belgique, 6 mai 2020, 7h00 – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires et biologiques innovantes répondant à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopédie et des maladies osseuses, publie aujourd’hui son rapport d’activité du premier trimestre, clôt le 31 mars 2020.« Malgré la pandémie de COVID-19, Bone Therapeutics a réalisé un excellent début d’année 2020, » commente Miguel Forte, MD, PhD, Directeur Général de Bone Therapeutics. « Nous avons notamment...

Continue reading

Santhera Signs Agreements in Gene Therapy Research for Congenital Muscular Dystrophy with Rutgers University

Pratteln, Switzerland, May 06, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of two agreements with Rutgers, The State University of New Jersey as part of its program to advance gene therapy research for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Under the agreements, Santhera gains rights to intellectual property developed at Rutgers on certain gene constructs that will be further studied under a collaboration agreement.Santhera has entered into a license agreement with Rutgers, The State University of New Jersey and a collaboration with Prof. Peter Yurchenco, a pioneer in a novel gene therapy approach for the treatment of LAMA2 MD. These agreements complement the ongoing collaboration of Santhera with Prof. Markus Rüegg from the Biozentrum of the University of Basel [1]. Previous...

Continue reading

Santhera geht Vereinbarungen zur gentherapeutischen Forschung bei kongentialer Muskeldystrophie mit der Rutgers-Universität ein

Pratteln, Schweiz, 6. Mai 2020 – Santhera Pharmaceuticals (SIX: SANN) hat im Rahmen seines Programms zur Förderung der gentherapeutischen Forschung für die Behandlung von LAMA2-defizienter kongenitaler Muskeldystrophie (LAMA2 MD oder MDC1A) mit Rutgers, der State University of New Jersey, zwei Vereinbarungen unterzeichnet. Gemäss dieser Übereinkommen erwirbt Santhera die Rechte an geistigem Eigentum, das bei Rutgers für bestimmte Genkonstrukte entwickelt wurde, welche im Rahmen eines Kooperationsabkommens weiter untersucht werden sollen.Santhera hat eine Lizenzvereinbarung mit Rutgers, der State University of New Jersey, abgeschlossen und ist eine Zusammenarbeit mit Prof. Peter Yurchenco, der als einer der Wegbereiter für einen neuartigen Gentherapie-Ansatz zur Behandlung von LAMA2 MD gilt, eingegangen. Diese Vereinbarungen ergänzen die...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.